Iovance Biotherapeutics Long Term Debt

As of the most recent data (June 2026), IOVA shows a long-term debt of $43M. That compares with $45M in the prior-year period — down 3.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IOVA's long-term debt is now $43M (was $45M) — a 3.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Iovance Biotherapeutics is outperforming or lagging.

Tracking IOVA's long-term debt over time shows whether Iovance Biotherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $43M That compares with $45M in the prior-year period — down 3.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Iovance Biotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $43M) with ownership activity and broader fundamentals.

Iovance Biotherapeutics's long-term debt is $43M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.